Skip to content

US · VSTM · BIOTECHNOLOGY

Verastem, Inc. (VSTM) intrinsic value and stock valuation

$6.33as of 2026-11-21 · Mkt cap 515.82M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Verastem, Inc. DCF and intrinsic value

InvestorsCraft values VSTM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from VSTM’s statements →

Verastem, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Needham, MA 02494 verastem.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$30.9M-19% 5y CAGRd
20112025
Net income
-$-209.47M
20112025
Free cash flow
-$-137.51M
20112025
Total equity
$57.2M-13.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$30.9M$10M$0.00$2.6M$2.05M
Operating income-$-170.13M-$-114.96M-$-92.08M-$-72.94M-$-61.41M
Net income-$-209.47M-$-130.64M-$-87.37M-$-73.81M-$-71.2M
EPSd-$-3.02M-$-3.66M-$-3.96M-$-4.57M-$-4.9M
Operating cash flow-$-137.51M-$-104.77M-$-86.46M-$-63.67M-$-53.5M
Capital expenditure$0.00-$-30K$0.00$0.00-$-200K
Free cash flow-$-137.51M-$-104.8M-$-86.46M-$-63.67M-$-53.7M
Total assets$246.4M$101.5M$149.7M$95.1M$108.7M
Total debt$76.9M$42.3M$41.6M$27.1M$3.18M
Net debt-$-128.12M-$-46.56M-$-36.35M-$-47.87M-$-18.07M
Total equity$57.2M-$-28.89M$57.4M$47.4M$87.6M
Cash and short-term investments$205M$88.8M$137.1M$87.9M$100.3M
Income statement
20252024202320222021
Revenue$30.9M$10M$0.00$2.6M$2.05M
Cost of revenue$5.3M$0.00$0.00$0.00$0.00
Gross profit$25.6M$10M$0.00$2.6M$2.05M
Research and development expenses$114.6M$81.3M$61.4M$50.6M$39.4M
Selling, general and administrative expenses$81.2M$43.6M$30.7M$25M$24.1M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$195.8M$125M$92.1M$75.5M$63.5M
Cost and expenses$201M$125M$92.1M$75.5M$63.5M
Interest income$4.07M$4.15M$6.21M$1.22M$180K
Interest expense$1.14M$4.56M$4.14M$2.14M$9.97M
Depreciation and amortization$730K$30K$60K$120K$70K
Ebitda-$-207.6M-$-125.86M-$-83.17M-$-71.56M-$-61.16M
Operating income-$-170.13M-$-114.96M-$-92.08M-$-72.94M-$-61.41M
Total other income/expenses, net-$-39.34M-$-15.5M$4.72M-$-880K-$-9.79M
Income before tax-$-209.47M-$-130.45M-$-87.37M-$-73.81M-$-71.2M
Income tax expense$0.00$180K$0.00$0.00$0.00
Net income-$-209.47M-$-130.64M-$-87.37M-$-73.81M-$-71.2M
Weighted average shares outstanding$69.3M$35.7M$22.1M$16.1M$14.5M
Weighted average diluted shares outstanding$69.3M$35.7M$22.1M$16.1M$14.5M
Balance sheet
20252024202320222021
Cash and short-term investments$205M$88.8M$137.1M$87.9M$100.3M
Net receivables$8.81M$200K$0.00$30K$520K
Inventory$1.83M$0.00$0.00$0.00$0.00
Total current assets$223.4M$95M$143.7M$92.9M$105.7M
Property, plant and equipment, net$490K$1.44M$1.21M$1.88M$2.51M
Goodwill and intangible assets$16.4M$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$240K$0.00
Total non-current assets$23M$6.58M$6.04M$2.18M$2.92M
Total assets$246.4M$101.5M$149.7M$95.1M$108.7M
Accounts payable$12.5M$4.03M$7.18M$4.9M$2.3M
Short-term debt$540K$990K$940K$1.07M$670K
Deferred revenue$0.00$0.00$0.00$710K$0.00
Total current liabilities$72.3M$31M$26.4M$21.7M$18.6M
Long-term debt$76.3M$41.3M$40.6M$26M$2.51M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$117M$99.5M$66M$26M$2.51M
Capital lease obligations$0.00$1.53M$1.47M$2.26M$2.93M
Total liabilities$189.3M$130.4M$92.3M$47.7M$21.1M
Common stock$10K$0.00$0.00$20K$20K
Retained earnings-$-1.17B-$-955.53M-$-824.89M-$-737.52M-$-663.71M
Accumulated other comprehensive income (loss)$5.23M$0.00$10K$0.00$30K
Total equity$57.2M-$-28.89M$57.4M$47.4M$87.6M
Total investments$0.00$0.00$59.2M$13.2M$79M
Total debt$76.9M$42.3M$41.6M$27.1M$3.18M
Net debt-$-128.12M-$-46.56M-$-36.35M-$-47.87M-$-18.07M
Cash flow statement
20252024202320222021
Net income-$-209.47M-$-130.64M-$-87.37M-$-73.81M-$-71.2M
Depreciation and amortization$730K$30K$60K-$-40K$70K
Stock-based compensation$9.4M$7.34M$5.86M$6.05M$7.71M
Change in working capital$26M$3.72M-$-960K$3.9M$580K
Accounts receivable-$-8.81M-$-200K$30K$480K-$-280K
Inventory-$-1.83M$0.00$0.00$0.00$0.00
Accounts payable$8.42M-$-3.16M$2.28M$2.6M$620K
Net cash provided by operating activities-$-137.51M-$-104.77M-$-86.46M-$-63.67M-$-53.5M
Investments in property, plant and equipment-$-9.62M-$-30K$0.00$0.00-$-200K
Acquisitions, net$0.00$0.00$0.00$0.00$9.33M
Net cash used for investing activities-$-9.62M$60M-$-44.45M$66.2M$90K
Common stock issued$230.9M$14.2M$91.4M$27.4M$6.72M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$263.3M$54.8M$134.2M$51.8M$6.88M
Net change in cash$116.2M$9.98M$3.29M$54.3M-$-46.53M
Cash at end of period$205.2M$89.1M$79.1M$75.8M$21.5M
Operating cash flow-$-137.51M-$-104.77M-$-86.46M-$-63.67M-$-53.5M
Capital expenditure$0.00-$-30K$0.00$0.00-$-200K
Free cash flow-$-137.51M-$-104.8M-$-86.46M-$-63.67M-$-53.7M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Verastem, Inc.

        Verastem, Inc. is an emerging biopharmaceutical company dedicated to the creation and commercialization of innovative therapeutic agents for cancer treatment. A primary asset in its pipeline is VS-6766, a novel dual RAF/MEK inhibitor that operates by a "clamp" mechanism. This unique action effectively blocks the kinase activity of MEK and disrupts RAF's ability to phosphorylate MEK. The company is actively advancing several clinical trials. RAMP 201 is an adaptive, two-part, multicenter, randomized, open-label study designed to assess both the efficacy and safety of VS-6766, administered alone or in combination with defactinib. Defactinib is an oral small molecule inhibitor of focal adhesion kinase (FAK), and this trial targets patients with recurrent low-grade serous ovarian cancer. Simultaneously, Verastem is conducting RAMP 202, a Phase 2 trial focused on evaluating the safety profile of VS-6766 combined with defactinib. This particular study enrolls patients with non-small cell lung cancer (NSCLC) that harbors KRAS and BRAF mutations, specifically after they have undergone treatment with platinum-based regimens and immune checkpoint inhibitors. Verastem has also forged strategic partnerships to support its development efforts. It holds license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacturing rights of products incorporating VS-6766. Additionally, a similar agreement with Pfizer Inc. pertains to the research, development, production, and marketing of Pfizer's FAK inhibitors for various human applications, including therapeutic, diagnostic, and prophylactic uses. Further expanding its collaborations, Verastem has a clinical agreement with Amgen, Inc. to explore the synergistic potential of VS-6766 alongside Amgen's KRAS-G12C inhibitor, LUMAKRAS™, a combination being investigated in the Phase 1/2 RAMP 203 trial. Founded in 2010, Verastem, Inc. maintains its corporate headquarters in Needham, Massachusetts.

        CEO
        Daniel W. Paterson
        Employees
        102
        Beta
        0.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Verastem, Inc. (VSTM)?

        Verastem, Inc. (VSTM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is VSTM undervalued?

        VSTM trades at a price of $6.33 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.